デフォルト表紙
市場調査レポート
商品コード
1763882

CRISPRベース診断市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

CRISPR-Based Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By End User, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 182 Pages
納期
2～3営業日
カスタマイズ可能
CRISPRベース診断市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年
出版日: 2025年06月30日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

CRISPRベース診断の世界市場は、2024年に31億6,000万米ドルと評価され、予測期間中にCAGR 17.02％で成長し、2030年には81億2,000万米ドルに達すると予測されています。

この市場は、正確でコスト効率が高く、迅速な分子診断ツールに対する需要の高まりにより急成長を遂げています。CRISPRベース診断は、遺伝子編集メカニズムを利用してDNAまたはRNA配列を高精度で検出し、感染症、遺伝性疾患、がんの早期発見を支援します。ポイントオブケア検査、個別化医療、コンパニオン診断におけるこれらのツールの応用の増加は、市場の採用を加速しています。研究投資の拡大、バイオテクノロジー企業と学術機関の共同研究、分散型検査へのシフトが成長をさらに後押ししています。これらの診断薬はサンプル調製を最小限に抑え、高度なラボのインフラを必要とせずに結果を提供するため、臨床環境にも遠隔地環境にも適しています。

市場概要
予測期間 2026-2030
市場規模：2024年 31億6,000万米ドル
市場規模：2030年 81億2,000万米ドル
CAGR：2025年～2030年 17.02%
急成長セグメント がん診断薬
最大市場 北米

市場促進要因

CRISPR技術とプラットフォーム開発の進展

主な市場課題

限られた臨床検証と標準化

主な市場動向

ポイントオブケアおよび在宅検査アプリケーションの拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のCRISPRベース診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（酵素、キットおよび試薬、ソフトウェアおよびライブラリ）
    • 技術別（Cas9、Cas12、その他）
    • 用途別（感染症診断、遺伝性疾患診断、がん診断、その他）
    • エンドユーザー別（病院・診療所、診断、研究所、製薬・バイオテクノロジー企業、その他）
    • 企業別（2024）
    • 地域別
  • 市場マップ

第6章 北米のCRISPRベース診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のCRISPRベース診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のCRISPRベース診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のCRISPRベース診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのCRISPRベース診断市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Thermo Fisher Scientific Inc.
  • Integrated DNA Technologies, Inc.
  • Molbio Diagnostics
  • Horizon Discovery
  • Synthego Corporation
  • Mammoth Biosciences
  • Sherlock Biosciences
  • Caribou Biosciences
  • CrisprBits
  • ToolGen Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 29924

The Global CRISPR-Based Diagnostics Market was valued at USD 3.16 billion in 2024 and is projected to reach USD 8.12 billion by 2030, growing at a CAGR of 17.02% during the forecast period. This market is witnessing rapid growth due to rising demand for accurate, cost-efficient, and fast molecular diagnostic tools. CRISPR-based diagnostics utilize gene-editing mechanisms to detect DNA or RNA sequences with high precision, aiding early identification of infectious diseases, genetic conditions, and cancers. The increasing application of these tools in point-of-care testing, personalized medicine, and companion diagnostics is accelerating market adoption. Growth is further fueled by expanding research investments, collaborations between biotech firms and academic institutions, and a shift toward decentralized testing. These diagnostics offer results with minimal sample preparation and without the need for advanced lab infrastructure, making them well-suited for both clinical and remote environments.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.16 Billion
Market Size 2030USD 8.12 Billion
CAGR 2025-203017.02%
Fastest Growing SegmentCancer Diagnostics
Largest MarketNorth America

Key Market Drivers

Advancements in CRISPR Technology and Platform Development

Technological progress in CRISPR systems and platform innovations is significantly contributing to market growth. Enhanced enzyme engineering has improved the specificity and efficiency of Cas variants like Cas12, Cas13, and Cas14, enabling detection of multiple biomarkers with reduced off-target effects. Developments in portable diagnostic formats-such as lateral-flow strips, paper-based assays, and microfluidic devices-have made CRISPR tools accessible and easy to use, even outside of laboratory settings. Integration with AI for guide RNA design and interpretation software has improved diagnostic accuracy and user experience. Public-sector initiatives are also fostering innovation; for example, the NIH's Somatic Cell Genome Editing (SCGE) Program allocated USD 89 million in 2024 to improve genome-editing technologies, while a USD 27 million project launched a Genomics Learning Health System Network to incorporate genomic diagnostics into routine care.

Key Market Challenges

Limited Clinical Validation and Standardization

Despite promising laboratory results, CRISPR-based diagnostics face hurdles due to limited clinical validation and lack of standardization. Large-scale, peer-reviewed clinical trials evaluating these technologies across diverse populations and biological sample types are still sparse. Many current assays lack proven efficacy in complex samples such as blood or saliva, where potential interferences can compromise accuracy. This insufficient validation presents challenges for regulatory approvals and delays adoption in clinical settings. Medical institutions require comprehensive, reproducible evidence to trust and implement new diagnostic platforms, and the current data gaps hinder wider integration into healthcare systems.

Key Market Trends

Expansion of Point-of-Care and At-Home Testing Applications

The move toward decentralized diagnostic solutions is shaping the growth trajectory of CRISPR-based diagnostics. Traditional lab-based diagnostics can be slow and require skilled personnel, but CRISPR platforms offer a quicker, simpler alternative. Innovations in lyophilized reagents, compact lateral flow systems, and microfluidic devices have paved the way for CRISPR-based tests suitable for primary care, pharmacies, and even home use. These solutions are particularly valuable in low-resource or rural settings. Growing interest in remote healthcare and instant diagnostic results-especially for infectious diseases, chronic conditions, and genetic screening-is fueling demand. Additionally, smartphone-compatible, user-operated devices are gaining popularity among consumers. Features such as disposable cartridges, refrigeration-free storage, and minimal training requirements are making CRISPR diagnostics increasingly viable for widespread, non-laboratory applications.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Integrated DNA Technologies, Inc.
  • Molbio Diagnostics
  • Horizon Discovery
  • Synthego Corporation
  • Mammoth Biosciences
  • Sherlock Biosciences
  • Caribou Biosciences
  • CrisprBits
  • ToolGen Inc.

Report Scope:

In this report, the Global CRISPR-Based Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CRISPR-Based Diagnostics Market, By Product:

  • Enzymes
  • Kits and Reagents
  • Software and Libraries

CRISPR-Based Diagnostics Market, By Technology:

  • Cas9
  • Cas12
  • Others

CRISPR-Based Diagnostics Market, By Application:

  • Infectious Disease Diagnostics
  • Genetic Disorder Diagnostics
  • Cancer Diagnostics
  • Others

CRISPR-Based Diagnostics Market, By End User:

  • Hospitals and Clinics Diagnostic
  • Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others

CRISPR-Based Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CRISPR-Based Diagnostics Market.

Available Customizations:

Global CRISPR-Based Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global CRISPR-Based Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Enzymes, Kits and Reagents, Software and Libraries)
    • 5.2.2. By Technology (Cas9, Cas12, Others)
    • 5.2.3. By Application (Infectious Disease Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others)
    • 5.2.4. By End User (Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and Biotechnology Companies, Others)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America CRISPR-Based Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CRISPR-Based Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Mexico CRISPR-Based Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Canada CRISPR-Based Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe CRISPR-Based Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France CRISPR-Based Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany CRISPR-Based Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom CRISPR-Based Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy CRISPR-Based Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain CRISPR-Based Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific CRISPR-Based Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China CRISPR-Based Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India CRISPR-Based Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. South Korea CRISPR-Based Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Japan CRISPR-Based Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia CRISPR-Based Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America CRISPR-Based Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil CRISPR-Based Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina CRISPR-Based Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia CRISPR-Based Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa CRISPR-Based Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa CRISPR-Based Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia CRISPR-Based Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE CRISPR-Based Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Integrated DNA Technologies, Inc.
  • 15.3. Molbio Diagnostics
  • 15.4. Horizon Discovery
  • 15.5. Synthego Corporation
  • 15.6. Mammoth Biosciences
  • 15.7. Sherlock Biosciences
  • 15.8. Caribou Biosciences
  • 15.9. CrisprBits
  • 15.10. ToolGen Inc.

16. Strategic Recommendations

17. About Us & Disclaimer